The Treasury Department and Internal Revenue Service added cannabis tax guidance to their annual priorities, placing it on the 2026–2027 Priority Guidance Plan released September 29. The plan covers October 1, 2026, through September 30, 2027. It sets no deadline for the work.
The listed project, “Guidance under §280E,” is one of 121 projects on the plan. Treasury and the IRS said listed items “will be the focus of our efforts during the plan year.” The designation signals attention, not a promised release date.
For marijuana businesses, the intended subject is how 26 U.S.C. §280E applies following federal rescheduling developments. The plan does not itself change the tax treatment of an operator or establish when any relief would take effect.
Free toolSubstantial Presence Test Calculator
That leaves companies waiting for specifics. Treasury and the IRS have already described the broader tax issue, but the priority list does not resolve questions about businesses combining medical and adult-use sales.
Earlier agency statements tied tax treatment to rescheduling
Treasury and the IRS announced on April 23, 2026, that they planned to issue tax guidance connected to the rescheduling action. Commentators have pointed to an April 28, 2026, Department of Justice final rule affecting certain marijuana products and state medical marijuana activity.
In their April statement, Treasury and the IRS said rescheduling would “generally remove[] section 280E as a bar to claiming deductions and credits” for businesses no longer trafficking in Schedule I or II controlled substances. They also indicated that future guidance would clarify how to apportion expenses when a business conducts multiple activities.
That explanation frames the issue, but it does not settle every operator’s tax position.
The agencies have also described why they publish guidance priorities: to identify and prioritize tax issues and “increase voluntary compliance by helping to clarify ambiguous areas of the tax law.” The new listing puts the cannabis issue among the projects they say will receive attention during the plan year.
The controlled-substance schedule affects the deduction question
Section 280E generally disallows deductions and credits for businesses trafficking in Schedule I or Schedule II controlled substances. The rule has long shaped federal tax treatment for cannabis operators because ordinary business deductions can be unavailable when the business falls within its scope.
Commentary on the rescheduling developments says state-licensed medical marijuana activities moved to Schedule III may no longer face the same restriction for covered activity. That possibility is tied to the scope of the action and the business activity involved. The guidance has not yet provided a final account of how those conditions apply across different operations.
Adult-use marijuana presents a separate question. Industry analyses say adult-use activity generally remains subject to §280E unless broader federal scheduling changes take effect. As a result, a change affecting qualifying medical activity does not, by itself, establish that every cannabis business can claim deductions and credits.
The distinction runs through the products and activities an operator handles. A company with only covered medical activity may face a different analysis from an adult-use seller, while a business operating in both areas may need to account for them separately. The agencies have not finalized those details in the priority list.
Mixed operators need answers on apportionment and timing
Companies with both medical and adult-use operations face two related questions: how to allocate shared expenses and when any change in treatment begins. Treasury and the IRS previously said guidance would address apportionment for businesses with multiple activities, making that issue central for operators whose costs support more than one line of business.
Commentary on the priority project also identifies a possible transition rule. The list itself does not set out such a rule or say when relief would begin. That leaves open how the agencies will treat activity spanning the rescheduling change and whether an operator can apply a revised approach to an earlier period.
The timing issue remains unresolved for tax year 2026 returns. Analysts have raised questions about whether any relief would apply automatically to businesses or depend on conditions connected to the April 2026 action and a registration process. Those questions remain unresolved in the material published as part of the priority designation.
The designation is not final guidance, a guaranteed effective-date change or automatic tax relief. Businesses therefore cannot treat the appearance of the project on the plan as an agency determination about their own deductions. The tax result may turn on the schedule involved, the activities conducted and the eventual agency treatment of mixed operations.
Treasury and the IRS have not attached a completion date to the project. The plan year ends September 30, 2027, but that date marks the end of the listed planning period, not a deadline for issuing the cannabis guidance.
This article is for informational purposes only and does not constitute tax advice. Consult a qualified tax professional or CPA about your specific situation.
